UroGen Pharma Ltd. (URGN): Results of Operations and Financial Condition
UroGen Pharma Ltd. (URGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_995856.htm EXHIBIT 99.1 ex_995856.htm Exhibit 99.1 UroGen Reports $50.4 Million of ZUSDURI ® Revenue and Provides Second Quarter 2026 Financial Results and Highlights ● ZUSDURI ® generated $50.4 million in revenue in the second quarter of 2026, representing 73% quart
How this was made
The 30-second read
Why it matters
Key trading inputs are the Q2 revenue prints for ZUSDURI and JELMYTO, the Notice of Allowance for a new US patent with expected protection into July 2044, and the reiterated timeline for UGN-103 NDA submission in Q3 2026 plus UGN-501 Phase 1 initiation in Q4 2026.
Market read
Traders can update models for ZUSDURI commercial trajectory and incorporate the next regulatory and clinical catalysts (UGN-103 NDA timing, UGN-501 Phase 1 start) alongside the IP extension narrative.
What to watch
The Teva settlement grants a future non-exclusive generic license starting September 15, 2030, which could cap long-term upside despite the July 2044 patent coverage narrative.
Background
This is an SEC Form 8-K (Item 2.02) with Exhibit 99.1 summarizing UroGen’s Q2 2026 financial results and pipeline/commercial updates.
Ticker impact
UroGen reported Q2 2026 ZUSDURI revenue of $50.4M, added patent allowance expected to extend protection into July 2044, and reiterated UGN-103 NDA timing for Q3 2026.
Near-term upside bias as traders price in durable franchise/IP extension and the upcoming NDA/Phase 1 milestones; volatility likely around biotech execution risk.
All cited items are primary disclosures in the 8-K exhibit: Q2 revenue, patent notice of allowance with stated expected coverage period, and explicit planned timing for NDA submission and trial initiation.
Market effects
Reinforces investor focus on bladder cancer intravesical therapies with durable response and IP life-cycle strategies.
Limited, primarily affects US small/mid-cap biotech sentiment.
Low; the catalysts are company-specific and US regulatory/patent related.
Counterpoint
Revenue growth and patent coverage may not translate into near-term earnings power if payer coverage, utilization durability, or competitive dynamics weaken.
Key entities
- companyUroGen Pharma Ltd.
Subject of the 8-K, reporting Q2 2026 results and providing updates on ZUSDURI, JELMYTO, and pipeline milestones.
- productZUSDURI
Mitomycin intravesical solution; reported $50.4M Q2 2026 revenue and durability data, plus patent allowance coverage into July 2044.
- pipeline_programUGN-103
Next-generation mitomycin-based therapy; on track for NDA submission in Q3 2026 and potential approval in 2027.
- pipeline_programUGN-501
Investigational oncolytic virus; FDA IND accepted with planned Phase 1 initiation in Q4 2026.
- counterpartyTeva Pharmaceuticals
Entered into a settlement and license agreement resolving JELMYTO generic patent litigation, with a non-exclusive license contingent on FDA approval.
